BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
(NASDAQ:ONC) SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the f
Related Questions
How might the positive topline results for sonrotoclax affect BeOne's stock price in the short term?
What are the key differences in efficacy and safety between sonrotoclax and existing BCL2 inhibitors or competing therapies for relapsed/refractory mantle cell lymphoma?
What are the expected regulatory timelines and additional funding requirements to advance sonrotoclax to Phase 3 and eventual market launch, and how could these impact future dilution or cash flow?